Contract Development Manufacturing Organization (CDMO) Vendors and CDMO Market Trend

Contract Development Manufacturing Organization (CDMO) is a set of pharmacy development based on the client's project (Chemical Manufacturing and Control). CDMO includes early molecular design and construction, drug development, and quality property studies of drug manufacturing. CDMO services for biologics mainly include cell line construction related to cell culture, cell culture process optimization, antibody expression and pilot production, antibody commercial production and preparation, etc. Based on cell culture and antibody expression, they are used throughout the process of biologics R&D and production.

The global CDMO market size is expected to grow from USD 29.7 billion in 2017 to USD 57.2 billion by 2022, with a CAGR of 14.0% from 2017 to 2022. The global CDMO market size is expected to reach USD 104.6 billion in 2027, with a CAGR of 12.8% from 2022 to 2027.

Figure 2017-2027 Global CDMO Market Size (Billion USD) and CAGR

The global CDMO industry is highly fragmented. The top 3 players are LONZA, Catalent, and Samsung Biologics with a total share of 29.2%.